Actively Recruiting
Study of Casdatifan Pharmacokinetics in Adults with Moderate Liver Impairment Compared to Healthy Controls
Led by Arcus Biosciences, Inc. · Updated on 2026-09-04
16
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how the drug casdatifan behaves in the bodies of adults with moderate liver impairment compared to healthy adults with normal liver function. This Phase 1, open-label study focuses on understanding differences in the drugs concentration over time between these two groups. The study is sponsored by Arcus Biosciences, Inc. and aims to provide basic scientific insights into casdatifans pharmacokinetics in these populations. Participants will receive a single 100 mg oral dose of casdatifan. There are two groups in the study one with moderate hepatic impairment classified by the Child-Pugh system, and one with healthy control participants matched by relevant factors. The study is designed with parallel groups and no randomization or blinding. Drug levels and related measures will be tracked up to 10 days after dosing, with safety monitored through adverse event recording up to 23 days post-dose. During the study, participants will undergo clinical evaluations including physical exams, laboratory tests, vital signs, and ECGs to confirm eligibility and monitor health. Researchers will measure the drugs concentration over time in plasma, including peak levels and clearance rates. Safety assessments will capture any adverse events experienced. The total participation lasts up to about three weeks, including dosing and follow-up periods to ensure comprehensive pharmacokinetic and safety data collection.
CONDITIONS
Brief Title
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
Research Team
M
Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here